Bronwyn Brophy O´Connor, CEO Vitrolife AB, has acquired 19,350 shares worth 2,495,957 SEK. The total holdings of shares amount to 19,350.
The transaction will be reported to The Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations.
"I am delighted to invest in the Vitrolife Group as I see great opportunities ahead as we strive to become the global leader in reproductive health," says Bronwyn Brophy O´Connor.
Gothenburg, September 14, 2023
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.
Vitrolife Group's products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: email@example.com. Website: www.vitrolifegroup.com.
(c) 2023 Cision. All rights reserved., source Press Releases - English